지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2018.1
- 수록면
- 488 - 494 (7page)
이용수
초록· 키워드
오류제보하기
Purpose The optimal treatment strategy for patients with metastatic non-clear cell type renal cell carcinoma (nccRCC) remains unclear. Although several inhibitors of vascular endothelial growth factor have recently shown efficacy against nccRCC, the clinical benefit of pazopanib in nccRCC has not been analyzed. We therefore designed a single-arm, open-label, phase II study to determine the efficacy and safety of pazopanib in patients with nccRCC. Materials and Methods Patients with locally advanced or metastatic nccRCC, except for collecting duct or sarcomatoid type, received 800 mg/day of pazopanib daily until progression of disease or intolerable toxicity. One cycle was defined as 4 weeks and tumor response was evaluated every two cycles. The primary objective was overall response rate (ORR). Results A total of 29 eligible patients were enrolled at nine centers in Korea from December 2012 and September 2014. The median age of the patients was 58 years (range, 27 to 76 years) and 21 patients (72%) were male. Regarding histology type, 19 patients had papillary, three had chromophobe, two had unclassified and five had unknown non-clear cell type. Of 28 evaluable patients, eight achieved a confirmed partial response with ORR of 28%. The median progression-free survival was 16.5 months (95% confidence interval, 10.9 to 22.1) and median overall survival was not reached. Sixteen patients (55%) experienced treatment- related toxicity of grade 3 or more, but most adverse events were overcome through dose reduction and delay. Conclusion In this prospective phase II study, pazopanib demonstrated promising activity and tolerable safety profile in patients with metastatic nccRCC.
목차
등록된 정보가 없습니다.
참고문헌 (26)
참고문헌 신청
Leibovich BC / 2010 / Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma / J Urol 183:1309~1315
Motzer RJ / 2002 / Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology / J Clin Oncol 20:2376~2381
Vera-Badillo FE / 2015 / Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis / Eur Urol 67:740~749
National Comprehensive Cancer Network / 2016 / NCCN clinical practice guidelines in oncology, kidney cancer. version 2. 2016 [Internet]
Dutcher JP / 2009 / Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies / Med Oncol 26:202~209
Motzer RJ / 2002 / Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology / J Clin Oncol 20:2376~2381
Vera-Badillo FE / 2015 / Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis / Eur Urol 67:740~749
National Comprehensive Cancer Network / 2016 / NCCN clinical practice guidelines in oncology, kidney cancer. version 2. 2016 [Internet]
Dutcher JP / 2009 / Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies / Med Oncol 26:202~209
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea
Cancer Research and Treatment
2016 .01
-
신장암 환자에서 Pazopanib을 사용한 후 발생한 심부전 1예
대한내과학회지
2016 .01
-
혈액투석 환자에서 발생한 카포시육종의 Pazopanib 치료 증례
대한내과학회지
2015 .01
-
Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response
Cancer Research and Treatment
2023 .04
-
Real-World Effectiveness of Pazopanib on Advanced Synovial Sarcoma: Meta-Analysis
보건의료기술평가
2023 .06
-
Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study
Journal of Gynecologic Oncology
2017 .01
-
Efficacy and Toxicity of Sunitinib in Metastatic Renal Cell Carcinoma Patients in Egypt
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Gray Hair Associated with the Multitargeted Receptor Tyrosine Kinase Inhibitor Pazopanib
Annals of Dermatology
2015 .01
-
Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study
Journal of Gynecologic Oncology
2018 .01
-
Metastatic Renal Cell Carcinoma in the Paranasal Sinus: A Case Report and Literature Review
대한이비인후-두경부외과학회지
2016 .01
-
Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database
Investigative and Clinical Urology
2020 .01
-
Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma who Received Systemic Treatment
Cancer Research and Treatment
2021 .10
-
Laparoscopic total pancreatectomy for multiple metastasis of renal cell carcinoma of the pancreas : a case report and literature review
Annals of Hepato-Biliary-Pancreatic Surgery
2017 .05
-
Establishment of patient-derived three-dimensional organoid culture in renal cell carcinoma
Investigative and Clinical Urology
2020 .01
-
A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer
Cancer Research and Treatment
2022 .07
-
Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08
Cancer Research and Treatment
2016 .01
-
Renal Cell Carcinoma Recognized Incidentally during Long-term Lithium Treatment
전남의대학술지
2016 .01
-
Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial
Clinical and Molecular Hepatology
2020 .01
-
International, multicenter, and prospective trials for treatment of HCC
Annals of Hepato-Biliary-Pancreatic Surgery
2021 .12
-
A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC): In-Depth Analysis of Nintendanib Arm from the KCSG HN 15-16 TRIUMPH Trial
Cancer Research and Treatment
2024 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0